XML 35 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue Recognition and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition and Concentration of Credit Risk Revenue Recognition and Concentration of Credit Risk
During the years ended December 31, 2023, 2022 and 2021, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:
Customer2023 Revenue% of Total
Revenue		2022 Revenue% of Total
Revenue		2021 Revenue% of Total
Revenue
ApolloBio Corporation$245,056 29 %$— — %$— — %
Plumbline Life Sciences, Inc. (affiliated entity)— — 33,596 — 245,310 14 
U.S. Department of Defense— — 9,591,778 94 754,853 43 
All other, including affiliated entities586,954 71 636,894 6 774,595 43 
Total revenue$832,010 100 %$10,262,268 100 %$1,774,758 100 %

No revenue recognized during the year ended December 31, 2023 was in deferred revenue as of December 31, 2022. During the year ended December 31, 2022, the Company recognized revenue of $14,000 that was included in deferred revenue at December 31, 2021. Performance obligations are generally satisfied within 12 months of the initial contract date.
As of December 31, 2023, the Company had no accounts receivable balance. As of December 31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. There is minimal credit risk with the Company's customers based upon the short-term nature of the accounts receivable, collection history, their size and financial condition. Accordingly, the Company does not record an allowance for potential credit losses against its accounts receivable.